[Special Stock] Syswork Gains Attention as Samsung Moderna Vaccine Contract Manufacturing Collaboration and No.1 in Cleanroom Control System Market Highlighted

[Asia Economy Reporter Minwoo Lee] Syswork's stock price is on the rise. The news that Samsung Electronics is directly overseeing the contract manufacturing of Moderna's COVID-19 vaccine in the United States appears to have acted as a positive factor. Since Moderna's messenger ribonucleic acid (mRNA) vaccine bulk solution requires strict clean management, Syswork's history of supplying semiconductor 'cleanroom' related components to Samsung Electronics has been highlighted.

As of 9:57 AM on the 2nd, Syswork's stock price recorded 2,470 KRW, up 6.24% compared to the previous trading day. The news that Samsung Electronics is pursuing a plan to assist Moderna's domestic contract manufacturing organization (CMO) for the COVID-19 vaccine seems to have had a positive impact. This is interpreted as support for Samsung Biologics amid concerns over supply delays caused by production disruptions at European factories. Samsung Biologics signed a contract for vaccine contract manufacturing with Moderna in May, being the only company in Asia to do so.

Samsung Electronics is expected to support 'cleanroom' technologies used for error-free semiconductor drug product (DP) filling and packaging. Accordingly, Syswork's supply of cleanroom technology-related components to Samsung Electronics is seen as a favorable factor. Syswork, ranked first in the domestic cleanroom control system market share, manufactures monitoring and control systems for FFU and EFU used in cleanrooms, as well as BLDC motors used in heating, cooling, and ventilation systems. It trades with four domestic FFU specialized companies, and these products are reportedly supplied to domestic and international semiconductor and display companies such as Samsung Electronics, LG Electronics, and SK Hynix.